The DOI matches its Crossref record; 240 of the 240 references it cites were found in a registry or an index.
Improvement of conventional anti-cancer drugs as new tools against multidrug resistant tumors
Open accessAbstract
Multidrug resistance (MDR) is the dominant cause of the failure of cancer chemotherapy. The design of antitumor drugs that are able to evade MDR is rapidly evolving, showing that this area of biomedical research attracts great interest in the scientific community. The current review explores promising recent approaches that have been developed with the aim of circumventing or overcoming MDR. Encouraging results have been obtained in the investigation of the MDR-modulating properties of various classes of natural compounds and their analogues. Inhibition of P-gp or downregulation of its expression have proven to be the main mechanisms by which MDR can be surmounted. The use of hybrid molecules that are able to simultaneously interact with two or more cancer cell targets is currently being explored as a means to circumvent drug resistance. This strategy is based on the design of hybrid compounds that are obtained either by merging the structural features of separate drugs, or by conjugating two drugs or pharmacophores via cleavable/non-cleavable linkers. The approach is highly promising due to the pharmacokinetic and pharmacodynamic advantages that can be achieved over the independent administration of the two individual components. However, it should be stressed that the task of obtaining successful multivalent drugs is a very challenging one. The conjugation of anticancer agents with nitric oxide (NO) donors has recently been developed, creating a particular class of hybrid that can combat tumor drug resistance. Appropriate NO donors have been shown to reverse drug resistance via nitration of ABC transporters and by interfering with a number of metabolic enzymes and signaling pathways. In fact, hybrid compounds that are produced by covalently attaching NO-donors and antitumor drugs have been shown to elicit a synergistic cytotoxic effect in a variety of drug resistant cancer cell lines. Another strategy to circumvent MDR is based on nanocarrier-mediated transport and the controlled release of chemotherapeutic drugs and P-gp inhibitors. Their pharmacokinetics are governed by the nanoparticle or polymer carrier and make use of the enhanced permeation and retention (EPR) effect, which can increase selective delivery to cancer cells. These systems are usually internalized by cancer cells via endocytosis and accumulate in endosomes and lysosomes, thus preventing rapid efflux. Other modalities to combat MDR are described in this review, including the pharmaco-modulation of acridine, which is a well-known scaffold in the development of bioactive compounds, the use of natural compounds as means to reverse MDR, and the conjugation of anticancer drugs with carriers that target specific tumor-cell components. Finally, the outstanding potential of in silico structure-based methods as a means to evaluate the ability of antitumor drugs to interact with drug transporters is also highlighted in this review. Structure-based design methods, which utilize 3D structural data of proteins and their complexes with ligands, are the most effective of the in silico methods available, as they provide a prediction regarding the interaction between transport proteins and their substrates and inhibitors. The recently resolved X-ray structure of human P-gp can help predict the interaction sites of designed compounds, providing insight into their binding mode and directing possible rational modifications to prevent them from becoming P-gp drug substrates. In summary, although major efforts were invested in the search for new tools to combat drug resistant tumors, they all require further implementation and methodological development. Further investigation and progress in the abovementioned strategies will provide significant advances in the rational combat against cancer MDR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–240 of 240
Gu, X., Huang, Z., Ren, Z., Tang, X., Xue, R., Luo, X., Peng, S., Peng, H., Lü, B., Tian, J., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01075 · Cited by 39
Identification of new P-glycoprotein inhibitors derived from cardiotonic steroids
Zeino, M., Paulsen, M. S., Zehl, M., Urban, E., Kopp, B., & Efferth, T. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2014.10.009 · Cited by 38
Pajeva, I. K., Sterz, K., Christlieb, M., Steggemann, K., Marighetti, F., & Wiese, M. (2013) · ChemMedChem · doi:10.1002/cmdc.201300233 · Cited by 36
Self-citationBae, P. K., & Chung, B. H. (2014) · Nano Convergence · doi:10.1186/s40580-014-0023-5 · Cited by 36
Sinha, B. K., Bortner, C. D., Mason, R. P., & Cannon, R. E. (2018) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2018.08.021 · Cited by 36
Zhang, L., Liu, L., Zheng, C., Wang, Y., Nie, X., Shi, D., Chen, Y., Wei, G., & Wang, J. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.03.011 · Cited by 35
Liu, S., Zhang, K., Zhu, Q., Shen, Q., Zhang, Q., Yu, J., Chen, Y., & Lu, W. P. (2019) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2019.02.046 · Cited by 33
Prasad, V. V. S. R., Reddy, G. D., Kathmann, I., Amareswararao, M., & Peters, G. J. (2015) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2015.11.007 · Cited by 31
Mlejnek, P., Kosztyu, P., Doležel, P., Bates, S. E., & Ruzickova, E. (2017) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2017.06.012 · Cited by 31
Polymer-Drug Conjugates: Novel Carriers for Cancer Chemotherapy
Seifu, M. F., & Nath, L. K. (2018) · Polymer-Plastics Technology and Materials · doi:10.1080/03602559.2018.1466172 · Cited by 31
Liposomal Nitrooxy-Doxorubicin: One Step over Caelyx in Drug-Resistant Human Cancer Cells
Pedrini, I., Gazzano, E., Chegaev, K. Y., Rolando, B., Marengo, A., Kopecka, J., Fruttero, R., Ghigo, D., Arpicco, S., & Riganti, C. (2014) · Molecular Pharmaceutics · doi:10.1021/mp500257s · Cited by 30
Self-citationMiao, Q., Wang, Z., Zhang, Y., Miao, P., Zhao, Y.-Y., Zhang, Y., & Ma, S. (2016) · Pharmaceutical Biology · doi:10.3109/13880209.2015.1107744 · Cited by 29
Huang, X., Huang, R.-Z., Gou, S., Wang, Z., Liao, Z., & Wang, H. (2017) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2017.07.011 · Cited by 28
Fu, Q., Kang, K. W., & Han, H. (2012) · Biopharmaceutics & Drug Disposition · doi:10.1002/bdd.1811 · Cited by 27
Šubr, V., Sivák, L., Koziolová, E., Braunová, A., Pechar, M., Strohalm, J., Kabešová, M., Řı́hová, B., Ulbrich, K., & Kovář, M. (2014) · Biomacromolecules · doi:10.1021/bm500649q · Cited by 27
Exogenous donors of nitric oxide (a chemical aspect)
Granik, V. G., & Grigor"ev, N. B. (2002) · Russian Chemical Bulletin · doi:10.1023/a:1020994402835 · Cited by 27
Battistella, C., & Klok, H. (2017) · Biomacromolecules · doi:10.1021/acs.biomac.7b00291 · Cited by 26
Zhang, K., Lin, H., Mao, J., Luo, X., Wei, R., Su, Z., Zhou, B., Li, D., Gao, J., & Shan, H. (2019) · Biomaterials Science · doi:10.1039/c9bm00216b · Cited by 25
Podolski-Renić, A., Banković, J., Dinić, J., Ríos‐Luci, C., Fernandes, M. X., Ortega, N., Kovačević‐Grujičić, N., Martı́n, V. S., Padrón, J. M., & Pešić, M. (2017) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2017.05.011 · Cited by 24
Gupta, V. K., Bhalla, Y., & Jaitak, V. (2013) · Medicinal Chemistry Research · doi:10.1007/s00044-013-0612-6 · Cited by 23
CUDC-907, a dual HDAC and PI3K inhibitor, reverses platinum drug resistance
To, K. K. W., & Fu, L. (2017) · Investigational New Drugs · doi:10.1007/s10637-017-0501-9 · Cited by 23
Dinić, J., Podolski-Renić, A., Jovanović, M., Musso, L., Tsakovska, I., Pajeva, I. K., Dallavalle, S., & Pešić, M. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20184575 · Cited by 23
Self-citationZou, Z., Lan, X., Qian, H., Huang, W., & Li, Y. (2011) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2011.07.077 · Cited by 22
Modulation of P-gp expression by lapatinib
Dunne, G., Breen, L., Collins, D. M., Roche, S., CLYNES, M. M., & O'Connor, R. A. (2010) · Investigational New Drugs · doi:10.1007/s10637-010-9482-7 · Cited by 21
Research Progress on Reversing Multidrug Resistance in Tumors by Using Chinese Medicine
Zhao, H., Xie, H., Li, J., Ren, C., & Chen, Y. (2018) · Chinese Journal of Integrative Medicine · doi:10.1007/s11655-018-2910-1 · Cited by 21
Wang, Y., Jiang, Z., Yuan, B., Tian, Y., Xiang, L., Li, Y., Yang, Y., Li, J., & Wu, A. (2019) · Biomaterials Science · doi:10.1039/c9bm00337a · Cited by 21
Insights on the Mechanism of Action of INH-C 10 as an Antitubercular Prodrug
Vila‐Viçosa, D., Victor, B. L., Ramos, J., Machado, D., Viveiros, M., Switala, J., Loewen, P. C., Elvas‐Leitão, R., Martins, F. E. L., & Machuqueiro, M. (2017) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.7b00719 · Cited by 20
Self-citationNitric oxide and BCNU chemoresistance in C6 glioma cells: Role of S-nitrosoglutathione
Yang, D., Yin, J., Ju, T., Chen, L.-S., & Hsu, C. Y. (2004) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2004.02.010 · Cited by 19
Tang, X., Gu, X., Ai, H., et al. (2011) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2011.12.065 · Cited by 19
Hu, W., Zhao, J., Hua, W., & Gou, S. (2017) · Metallomics · doi:10.1039/c7mt00289k · Cited by 19
Eum, K., Ahn, S. K., Kang, H., & Lee, M. (2012) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-012-1446-0 · Cited by 18
Rullo, M., Niso, M., Pisani, L., Carrieri, A., Colabufo, N. A., Cellamare, S., & Altomare, C. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.10.043 · Cited by 18
Huang, Z., Wu, J., Zou, Y. S., Yuan, H., Zhang, Y., Fei, Y., Bhardwaj, A., Kaur, J. P., Knaus, E. E., & Zhang, Y. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01178 · Cited by 17
Cabrales, P., Scicinski, J. J., Reid, T. R., Kuypers, F. A., Larkin, S. K., Fens, M. H. A. M., Oronsky, A. L., & Oronsky, B. T. (2016) · Medical Oncology · doi:10.1007/s12032-016-0775-3 · Cited by 15
Zhang, Q., Zhai, S., Li, L., Li, X., Jiang, C., Zhang, C., & Yan, B. (2014) · Journal of Pharmacological Sciences · doi:10.1254/jphs.14050fp · Cited by 14
Kumbhar, P., Birange, S., Atavale, M., Disouza, J., & Manjappa, A. S. (2018) · Colloid & Polymer Science · doi:10.1007/s00396-018-4416-6 · Cited by 13
Li, H., Wang, K., Wan, Q., & Chen, Y. (2018) · Steroids · doi:10.1016/j.steroids.2018.11.018 · Cited by 12
Development of liposome as a novel adsorbent for artificial liver support system in liver failure
Shen, Y., Wang, Y., Shi, Y., Tian, H., Zhu, Q., & Ding, F. (2019) · Journal of Liposome Research · doi:10.1080/08982104.2019.1630644 · Cited by 11
Wei, Y., Poon, D. C., Fei, R., Lam, A. S. M., Au‐Yeung, S. C. F., & To, K. K. W. (2016) · Scientific Reports · doi:10.1038/srep25363 · Cited by 10
Zhang, L., Rong, Y., Zheng, J., Yang, C., Chen, Y., Wang, J., & Wei, G. (2018) · RSC Advances · doi:10.1039/c8ra06360e · Cited by 7
Cited by
Mechanisms of Multidrug Resistance in Cancer Chemotherapy
Bukowski, K., Kciuk, M., & Kontek, R. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21093233 · Cited by 1,757
Doxorubicin—An Agent with Multiple Mechanisms of Anticancer Activity
Kciuk, M., Gielecińska, A., Mujwar, S., Kołat, D., Kałuzińska-Kołat, Ż., Celik, I., & Kontek, R. (2023) · Cells · doi:10.3390/cells12040659 · Cited by 810
Overcoming cancer therapeutic bottleneck by drug repurposing
Zhang, Z., Zhou, L., Xie, N., Nice, E. C., Zhang, T., Cui, Y., & Huang, C. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00213-8 · Cited by 516
Theranostic Fluorescent Probes
Sharma, A., Verwilst, P., Li, M., Ma, D., Singh, N., Yoo, J., Kim, Y., Yang, Y., Zhu, J.-H., Huang, H., et al. (2024) · Chemical Reviews · doi:10.1021/acs.chemrev.3c00778 · Cited by 499
Asymmetric organocatalysis: an enabling technology for medicinal chemistry
Han, B., He, X.-H., Liu, Y.-Q., He, G., Peng, C., & Li, J.-L. (2021) · Chemical Society Reviews · doi:10.1039/d0cs00196a · Cited by 402
Metadata
- Authors
- Dallavalle, S., Dobričić, V., Lazzarato, L., Gazzano, E., Machuqueiro, M., Pajeva, I., Tsakovska, I., Zidar, N., & Fruttero, R.
- Venue
- Drug Resistance Updates
- Publisher
- Elsevier BV
- Published
- 2020-05
- Volume
- 50
- Pages
- 100682
- ISSN
- 1368-7646 (ISSN-L)
- OpenAlex
- W3005521705
- Cited by
- 318
- References
- 240
- FWCI
- 14.20
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.